139 related articles for article (PubMed ID: 35282410)
1. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers.
Angkasekwinai N; Sewatanon J; Niyomnaitham S; Phumiamorn S; Sukapirom K; Sapsutthipas S; Sirijatuphat R; Wittawatmongkol O; Senawong S; Mahasirimongkol S; Trisiriwanich S; Chokephaibulkit K
Vaccine X; 2022 Apr; 10():100153. PubMed ID: 35282410
[TBL] [Abstract][Full Text] [Related]
2. The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
Mahasirimongkol S; Khunphon A; Kwangsukstid O; Sapsutthipas S; Wichaidit M; Rojanawiwat A; Wichuckchinda N; Puangtubtim W; Pimpapai W; Soonthorncharttrawat S; Wanitchang A; Jongkaewwattana A; Srisutthisamphan K; Phainupong D; Thawong N; Piboonsiri P; Sawaengdee W; Somsaard T; Ritthitham K; Chumpol S; Pinyosukhee N; Wichajarn R; Dhepakson P; Iamsirithaworn S; Phumiamorn S
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455285
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K
Asian Pac J Allergy Immunol; 2023 Jul; ():. PubMed ID: 37466962
[TBL] [Abstract][Full Text] [Related]
5. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
Nantanee R; Aikphaibul P; Jaru-Ampornpan P; Sodsai P; Himananto O; Theerawit T; Sophonphan J; Tovichayathamrong P; Manothummetha K; Laohasereekul T; Hiransuthikul N; Hirankarn N; Puthanakit T;
Vaccine; 2022 May; 40(24):3320-3329. PubMed ID: 35513961
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand.
Hongjaisee S; Chawansuntati K; Sripan P; Rattanathammethee K; Sakkhachornphop S; Chaiwarith R; Sudjaritruk T; Supparatpinyo K; Wipasa J
Vaccine X; 2023 Aug; 14():100305. PubMed ID: 37155476
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.
Sudjaritruk T; Mueangmo O; Saheng J; Winichakoon P; Salee P; Wongjak W; Chaito T; Praparattanapan J; Nuket K; Solai N; Wipasa J; Chawansuntati K; Chaiwarith R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992147
[TBL] [Abstract][Full Text] [Related]
9. Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2- seropositive individuals.
Fernandes ER; Taminato M; de Souza Apostolico J; Gabrielonni MC; Lunardelli VAS; Maricato JT; Andersen ML; Tufik S; Rosa DS
J Allergy Clin Immunol Glob; 2023 May; 2(2):100083. PubMed ID: 36845213
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M
Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409
[TBL] [Abstract][Full Text] [Related]
11. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand.
Chawansuntati K; Sakkhachornphop S; Hongjaisee S; Freeouf S; Sripan P; Nusartsang N; Chaiwarith R; Sudjaritruk T; Supparatpinyo K; Wipasa J
Vaccine X; 2024 Jun; 18():100475. PubMed ID: 38549951
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study.
Phuensan P; Sirimongkolkasem J; Tantawichien T; Phannajit J; Kerr SJ; Hansasuta P; Chantharit P; Wongsa A; Fuengfoo P; Chittinandana A; Vareesangthip K; Chayakulkeeree M; Jangsirikul S; Schmidt A; Wanvimonsuk K; Winichakoon P; Kajeekul R; Prayoonwiwat W; Rerknimitr R
Heliyon; 2024 Jan; 10(1):e23246. PubMed ID: 38163241
[TBL] [Abstract][Full Text] [Related]
15. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers.
Prasithsirikul W; Pongpirul K; Nopsopon T; Phutrakool P; Pongpirul W; Samuthpongtorn C; Suwanwattana P; Jongkaewwattana A
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214675
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers.
Jantarabenjakul W; Sodsai P; Chantasrisawad N; Jitsatja A; Ninwattana S; Thippamom N; Ruenjaiman V; Tan CW; Pradit R; Sophonphan J; Wacharapluesadee S; Wang LF; Puthanakit T; Hirankarn N; Putcharoen O
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632395
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R; Suntronwong N; Phowatthanasathian H; Assawakosri S; Kanokudom S; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
Vaccine; 2022 Jan; 40(3):524-530. PubMed ID: 34893344
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
[TBL] [Abstract][Full Text] [Related]
20. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
Bueno SM; Abarca K; González PA; Gálvez NM; Soto JA; Duarte LF; Schultz BM; Pacheco GA; González LA; Vázquez Y; Ríos M; Melo-González F; Rivera-Pérez D; Iturriaga C; Urzúa M; Dominguez A; Andrade CA; Berrios RV; Canedo-Marroquín G; Covián C; Moreno-Tapia D; Saavedra F; Vallejos OP; Donato P; Espinoza P; Fuentes D; González M; Guzmán P; Muñoz-Venturelli P; Pérez CM; Potin M; Rojas A; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Oyarzún-Arrau A; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Sette A; Zeng G; Meng W; González-Aramundiz JV; Kalergis AM
medRxiv; 2021 Apr; ():. PubMed ID: 35441164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
